DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
Journal of Korean Medical Science
;
: 207-213, 2011.
Article
in English
| WPRIM
| ID: wpr-123289
ABSTRACT
DNA methyltransferase inhibitor, 5-azacitidine (AC) is effective in myelodysplastic syndromes (MDS) and can induce re-expression in cancer. We analyzed the methylation of 25 tumor suppressor genes in AC-treated MDS. Hypermethylation of CDKN2B, FHIT, ESR1, and IGSF4 gene was detected in 9/44 patients. In concordance with the clinical response, a lack of or decreased methylation in 4 patients with hematologic improvements and persistent methylation in 4 others with no response was observed. The mRNA expression of CDKN2B, IGSF4, and ESR1 was significantly reduced in MDS. Our results suggest that methylation changes contribute to disease pathogenesis and may serve as marker to monitor the efficacy of treatments.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Azacitidine
/
Myelodysplastic Syndromes
/
DNA Modification Methylases
/
Genes, Tumor Suppressor
/
DNA Methylation
/
Enzyme Inhibitors
Limits:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
English
Journal:
Journal of Korean Medical Science
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS